Search

Displaying results 1951 - 1960 of 5897 in total
  1. Drug

    Lotilaner

    go.drugbank.com/drugs/DB17992
    ApprovedInvestigationalVet approved

    [A260746, L47556] Lotilaner consists of two enantiomers: the S-enantiomer is active _in vivo_, while the R-enantiomer is reported to exhibit low biological activity. … [L47546] Lotilaner has largely been used for veterinary uses as an antiparasitic agent to treat flea and tick infestations in animals.

  2. Drug

    Vayarin

    go.drugbank.com/drugs/DB09328
    Approved

    Approximately 60% of the users who completed 12 weeks of therapy reported subjective benefits from treatment. … Vayarin is a novel therapy for ADHD that appears to be effective in several studies [L1501, L1502, L1503].

  3. Drug

    1D-myo-inositol 1,4,5-trisphosphate

    go.drugbank.com/drugs/DB03401
    Experimental

    Intracellular messenger formed by the action of phospholipase C on phosphatidylinositol 4,5-bisphosphate, which is one of the phospholipids that make up the cell membrane.

  4. Drug

    Piflufolastat F 18

    go.drugbank.com/drugs/DB14805
    ApprovedInvestigational

    Piflufolastat F18, also called [F-18]-DCFPyL, is a urea-based radiopharmaceutical that binds to PSMA and allows for the visualization of cancerous prostate tissue. … It was first approved by the FDA in May 2021 under the brand name Pylarify and aims to allow for earlier and more accurate detection of suspected prostate cancer metastases or recurrences.

  5. Drug

    Selpercatinib

    go.drugbank.com/drugs/DB15685
    ApprovedInvestigational

    Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although mult...

  6. Drug

    Cresol

    go.drugbank.com/drugs/DB11143
    Approved

    Ingestion of cresol induces toxicity in humans and can lead to burning of the mouth and throat, abdominal pain, and/or vomiting. … At concentrations normally found in the environment however, cresols do not pose any significant risk for the general population.

  7. Drug

    Doxofylline

    go.drugbank.com/drugs/DB09273
    Investigational

    Decreased affinity for adenosine receptors may account for the better safety profile of doxofylline compared to theophylline [L1169]. … In contrast with other xanthine derivatives, doxofylline does not significantly bind to adenosine alpha-1 or alpha-2 receptors and lacks stimulating effects.

  8. Drug

    ANA975

    go.drugbank.com/drugs/DB06490
    Experimental

    ANA975 is a toll-like receptor 7 agonist that is developed for the treatment of hepatitis C.

    Synonyms: THIAZOLO(4,5-D)PYRIMIDIN-2(3H)-ONE, 5-AMINO-3-(2,3-DI-O-ACETYL-.BETA.-D-RIBOFURANOSYL)-
  9. Drug

    Protein C

    go.drugbank.com/drugs/DB11312
    ApprovedInvestigational

    It is converted by the thrombin/thrombomodulin-complex on the endothelial cell surface to Activated Protein C (APC). … A lack of protein C in the body would lead to unchecked coagulation activation, resulting in thrombin generation and intravascular clot formation.

  10. Drug

    Chloroquine

    go.drugbank.com/drugs/DB00608
    ApprovedInvestigationalVet approved

    [A191655] It was the drug of choice to treat malaria until the development of newer antimalarials such as [pyrimethamine], [artemisinin], and [mefloquine].